Dishman Pharma has its eyes set on biotech CRO companies

By Susan Gotensparre

- Last updated on GMT

Related tags: Pharmacology

India's Dishman Pharmaceuticals & Chemicals is planning to snap
up biotech and nanotech contract research organisation (CRO)
companies in Europe and in the US within drug conjugates to expand
their biologics capability.

Ahmedabad-based Dishman has utilised recently acquired Swiss-based pharma service business company Carbogen Amcis to identify CRO acquisitions from core areas, such as the development and manufacturing of drug conjugates, to complement its own business, with at least one or two to be made in Europe and the US by the end of 2007. So far, no purchase have been made but plans to identify potential companies falling between $5 million and $20 million range have been put together.

The goal behind their acquisition strategy is to offer an expanded service to customers to enhance their drug development process and increase their profitability and revenue, according to the company. The group believes drug conjugates - which take the form of active compounds linked to carrier or targeting molecules - will expand on their biologics capability and mean that they are able to provide full-service to its clients.

" Understanding the needs of our pharmaceutical customers and sharing our experience of project management within a service business will enhance any acquisitions we make. The main advantage however will be in combining our existing service offerings with new ones in a way, which enhances the outsourcing of drug development​," Rhona McIntyre, European sales manager for Carbogen Amcis told

"The most important feature of an acquisition is complementarity of fit rather than geography. The Dishman group is already expanding in both India and China. Growth here however tends to be through establishing our own footprints rather than by acquisition. This allows us to ensure the same standards of service whilst taking advantage of local expertise and infrastructure​."

Carbogen Amcis employs 320 people and is a leading service provider within drug development and commercialisation services to the pharmaceutical and biopharmaceutical industry. It develops technology transfer procedures with other pharmaceutical service companies within Dishman, such as SynProTec, I03S to maximise the benefits to the customer and project.

Related news

Show more

Related products

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more